The survival rate for people with advanced bladder cancer is less than a year, making it the fourth most common cancer diagnosed in men. The bladder cancer patients who will benefit from immunotherapy are unknown to doctors.
Children with recurrent brain tumours tolerated the first in-human trial of a novel immunotherapy well, and many were able to experience unexpected months of a more normal life, according to researchers. Immunotherapy disables a natural enzyme that tumours hijack for their defence.
A startling 89 per cent of desmoplastic melanoma patients in a nationwide clinical study responded to immunotherapy (pembrolizumab) alone, indicating that many patients could avoid the potential side effects of combination therapies and achieve disease control with this course of treatment.
According to new research, a biomarker signature can predict how well kidney cancer patients will respond to immunotherapy before treatment even starts. This biomarker signature is made up of the number of immune cells in and around kidney tumours, the volume of dead cancer tissue, and mutat
Experiments on mice and human cells reveal that the number of specialised immune cells ready to combat skin cancer increased when a novel therapy prevented their egress from melanoma tumours.
CAR T-cell therapy, a sort of cancer treatment in which the immune system's T cells are trained to attack tumour cells, was found to be effective in mice with ovarian cancer, according to a study.
According to a study, CAR T-cell therapy, a type of cancer treatment in which the immune system's T cells are trained to attack tumour cells, is successful in mice with ovarian cancer.
According to MSD, Keytruda is the first cancer immunotherapy to be approved in India for the treatment of cervical cancer and the first immunotherapy to be approved as a first-line treatment for a significant sub-group of patients, who otherwise only had the option of chemotherapy as their t
Researchers revealed that Immunotherapies have improved the outcomes of many cancer patients, including those with melanoma. However, only a subset of patients benefit from these treatments.
A mechanism has been identified by researchers from the University of Michigan Rogel Cancer Center that explains why some patients' cancers grow in response to immunotherapy rather than shrinking.